Sjögren's disease & overlap diseases

Hydroxychloroquine dose-dependently reduces the risk of incident diabetes in primary Sjögren syndrome patients on glucocorticoids: a nationwide population-based cohort study

Arthritis Res TherPublished Retrospective cohort study

Authors' conclusion

Our study demonstrated that HCQ exposure significantly reduces the risk of developing diabetes in patients with pSS. While higher doses of glucocorticoids are associated with an increased diabetes risk, concurrent HCQ use mitigates this risk in a dose-dependent manner.

Study context

Population
Patients diagnosed with pSS, Taiwan's National Health Insurance Research Database, 2006–2015497 developed diabetes mellitus (DM)
Exposure
Hydroxychloroquine (HCQ) users vs HCQ nonusers
  • HCQ usersn = 4,874
  • HCQ nonusersn = 2,437reference
Outcome
Incident (new-onset) DM
Methodological detailsnationwide population-based, multivariate and stratified analyses, Kaplan-Meier method, Cox proportional hazard regression
  • Nationwide population-based
  • Multivariate and stratified analyses
  • Kaplan-Meier method
  • Cox proportional hazard regression

Main finding

As reported in the abstract

Incident DM · average follow-up 4.89 years
Each group vs HCQ nonusersAdjusted hazard ratio (95% CI)
HCQ 151-350 cDDD
0.600(0.454–0.794)
HCQ ≥ 351 cDDD
0.326(0.246–0.433)

Observational data: associations, not effects.

Further findings

DM risk with high-dose GC (≥ 151 cumulative defined daily dose (cDDD))

aHR (95% CI)
High-dose GC (≥ 151 cDDD)1.833 (1.410–2.383)

DM risk with high-dose HCQ (> 350 cDDD), incl. with high-dose GC (≥ 151 cDDD)

aHR (95% CI)P value
High-dose HCQ (> 350 cDDD)0.632 (0.421–0.948)P < 0.01

Original publication

Hydroxychloroquine dose-dependently reduces the risk of incident diabetes in primary Sjögren syndrome patients on glucocorticoids: a nationwide population-based cohort study. Arthritis Res Ther. Published 16 April 2025. doi:10.1186/s13075-025-03542-7

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.